Stocks · News reference
Filed: 2026-08-06 AccNo: 0000950103-26-011979 Size: 261 KB Item 1.01: Entry into a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Nicox SA announced an extension of its cash runway to beyond Q1 2028 with €8.4 million in cash as of August 31, 2026. The company expects an FDA approval milestone for NCX 470 by April 30, 2027, which would fund operations into 2029, with subsequent royalties potentially extending visibility further. Management changes include Doug Hubatsch transitioning to Chief Scientific Advisor and Siobhan Garbutt assuming leadership of the development team.
HC Wainwright & Co. analyst Yi Chen reiterates Bausch & Lomb (NYSE:BLCO) with a Buy and maintains $21 price target.
Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.